Drug
L-DOS47
L-DOS47 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 25.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
25.0%
Based on 1 completed trials
Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
3(75%)
Phase Distribution
Ph phase_1
3
75%
Ph phase_2
1
25%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
25.0%
1 of 4 finished
Non-Completion Rate
75.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(1)
Terminated(3)
Detailed Status
Terminated3
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
25.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
terminated375%
completed125%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_1
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
NCT04203641
terminatedphase_1
A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
NCT02309892
terminatedphase_2
A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma
NCT03891173
completedphase_1
A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47
NCT02340208
Clinical Trials (4)
Showing 4 of 4 trials
NCT04203641Phase 1
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
NCT02309892Phase 1
A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
NCT03891173Phase 2
A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma
NCT02340208Phase 1
A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4